Placebo exposure | NO2exposure | |||||||
---|---|---|---|---|---|---|---|---|
Subject no | Age | Sex | FEV1(% pred) | Baseline eNO (ppb) | ΔeNO (ppb) | Baseline eNO (ppb) | ΔeNO (ppb) | |
1 | 26 | F | 90 | 3.8 | 0.14 | 6.1 | –0.75 | |
2 | 30 | M | 93 | 10.5 | –0.62 | 9.2 | –0.98 | |
3 | 37 | F | 82 | 4.5 | 0.58 | 7.3 | –1.41 | |
4 | 51 | F | 90 | 3.5 | 0.56 | 4.1 | –0.21 | |
5 | 36 | F | 90 | 7.3 | –0.49 | 7.2 | –0.66 | |
6 | 34 | M | 113 | 7.4 | 0.37 | 7.6 | –0.22 | |
7 | 28 | M | 106 | 10.2 | –1.11 | 9.4 | –0.58 | |
8 | 35 | F | 86 | 3.3 | 0.97 | 4.6 | –0.72 | |
9 | 51 | F | 105 | 3.4 | 0.81 | 4.4 | –0.74 | |
10 | 23 | F | 85 | 9.1 | 1.63 | 11.2 | 0.06 | |
Mean (95% CI) | 35.1 | 94 | 6.3 | 0.28 (–0.30 to 0.86) | 7.1 | –0.621-150 (–0.32 to –0.92) |
ΔeNO is calculated from the pre-exposure baseline eNO level and the post-exposure area under the eNO vtime curve.17
↵1-150 p<0.01 compared with placebo.